A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators

Applied Health Economics and Health Policy

Volumn 13, Issue , 2015, Pages 13-20

  Hu, Shanlian ^a,b   Zhang, Yabing ^c   He, Jiangjiang ^a,b   Du, Lixia ^b   Xu, Mingfei ^d   Xie, Chunyan ^b   Peng, Ying ^b   Wang, Linan ^b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Health Development Research Center   (China)

^c SHANGHAI INSTITUTE OF TECHNOLOGY   (China)

^d Xuhui District   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; GENERIC DRUG; OFF PATENT ORIGINATOR; UNCLASSIFIED DRUG;

ARTICLE; CHINA; DRUG COST; DRUG MARKETING; GOVERNMENT; HUMAN; PROSPECTIVE PRICING; QUANTITATIVE ANALYSIS; REIMBURSEMENT; COST CONTROL; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; FEE; LEGISLATION AND JURISPRUDENCE; PHARMACOECONOMICS; PROCEDURES; STANDARDS; THERAPEUTIC EQUIVALENCE;

CHINA; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; HUMANS; REIMBURSEMENT MECHANISMS; THERAPEUTIC EQUIVALENCY;

EID: 84938418041     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0150-5     Document Type: Article

References (25)

1. Gorden GEL. The market status of non-patent drugs in China [in Chinese]. 2010 China Pharmaceutical Industry Report. Beijing: Beijing Science Press; 2010. p. 104–129.
2. Chinese State Development and Reform Commission. A notice of adjusting the drug pricing list [in Chinese]. Document no. 429. Beijing: State Development and Reform Commission; 2010.
3. Chinese Ministry of Health, State Council Office for Correcting Illegitimate Practice, National Development and Reform Commission, Ministry of Supervision, Ministry of Finance, State Administration for Industry and Commerce, State Food and Drug Administration. The normalization of drug bulk procurement in medical institutions [in Chinese]. Document no. 64. Beijing: Chinese State Council Office; 2010. Available at: www.nhfpc.gov.cn. Accessed 15 July 2010.
4. Chaudhury RR. Implementation of a programme of rational use of drugs in Delhi State. In: International experience in rational use of drugs. vol 2. Bangkok: The College of Public Health, Chulalongkorn University and UNESCO; 1994. p. 108–123.
5. Chinese Pharmaceutical Association, Research Center for Medicinal Policy pharmaceutical information brief. 2013. Available at: www.phirda.com. Accessed 13 Dec 2013.
6. Food China, Administration Drug. 12th Five-year plan for drug safety (2011–2015) [in Chinese]. Beijing: Chinese Food and Drug Administration; 2010.
7. Shanghai tries using bulk purchasing generic drug to reduce their price [in Chinese]. Medical and Pharmaceutical News. 2013.
8. Xie M. Interpretation of the “circular of the state council concerning the twelfth five-year plan of national drug safety” [in Chinese]. J Drug Eval. 2012;9(20):6–10.
9. Xie M. How to develop and validate the dissolution test on the quality criteria. Chin J Pharm. 2012;43(3):23–32.
10. Gu M, Hu C. Quality evaluation of dissolution for cefaclor capsules [in Chinese]. Guide Chin Med. 2012;17:20–1.
11. Yan X, Chen A, Qiu W, Jiang Y, Ho Q, Shao Y. Evaluation of dissolution in vitro of fluconazole capsules [in Chinese]. Pharm Today. 2012;22(3):142–7.
12. Jia M, Xie C, Yang H, Lian H, Wang Y. Evaluation of irbesartan tablets by dissolution profiles in different mediums. Pharm Today. 2012;22(11):649–52 [In Chinese].
13. Yang X, Xu L, Zhao X. Comparative studies on dissolution profiles of telmisartan tablets from different pharmaceutical manufacturers in three dissolution mediums [in Chinese]. China Med Pharm. 2012;2(13):108–10.
14. Liu Y, Li Z, Qin L, Chen Z, Fan Y, Dong S. Comparative study on dissolution profiles of loratadine preparations [in Chinese]. China Pharm. 2012;15(8):1152–5.
15. Li J, Zhang H, Zhuang X, Huang H. Dissolution evaluation of domestic simvastatin capsules [in Chinese]. China Pharm. 2012;15(4):490–2.
16. Lv J, Luo E, Jiang Z. Comparison of dissolution test among 6 kings of commercialized enteric-coated tablets of aspirin [in Chinese]. Chin J Clin Pharm. 2001;10(5):296–8.
17. Zhang YB, Hu SL, He J. Situation analysis of domestic off-patent originals and generics [in Chinese]. Chin Health Econ J. 2013;32(6):21–3.
18. World Health Organization. Technical report series, no. 937. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish inter-changeability (Annex 7). In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report. Geneva: WHO; 2006. Available at: http://whqlibdoc.who.int/trs/who_trs_937_eng.pdf.
19. Holtorf AP, Ji S. Pharmaceutical inter-changeability reference guide [monograph]. Basel: Health Outcomes Strategies and Abbott; 2013.
20. National Development and Reform Commission. A regulation of drug price administration method [in Chinese]. 2010. Policy document. Available at: www.nprc.gov.cn. Accessed 17 June 2010.
21. Lu FX. Innovative drug pricing should apply the method of economic evaluation. In: The 4th Asia ISPOR Huaxia Forum. Hong Kong: NetEase Finance; 2012.
22. Chinese Communist Party Central Committee and the State Council. On deepening the medical and health system reform [in Chinese]. Central Government Document no. 6. 2009. Available at: www.nhfpc.gov.cn.
23. EVIDEM Collaboration. Decision criteria: conceptual background, definitions, design and instructions [monograph]. Montreal: EVIDEM; 2013. Available at: https://www.evidem.org/docs/2014/EVIDEM-v2-3-Decision-criteria-2013-12-24.pdf. Accessed 24 Dec 2013.
24. Dodgson JS, Spackman M, Pearman A, Phillips LD. Multi-criteria analysis: a manual. 2009. Available at: www.communities.gov.uk. Accessed 15 Apr 2014.
25. Chinese Ministry of Health. Implementation. Opinion on the establishment of national essential medicine system [in Chinese]. MOH document No. 78. 2009. Policy document. Available at: www.nhfpc.gov.cn. Accessed 18 Aug 2009.